European Journal of Medicinal Chemistry Reports, published by ELSEVIER, is a vital platform dedicated to advancing the field of medicinal chemistry through open access communication of high-quality research. With an impact factor reflecting its growing influence, this journal has rapidly established a reputation for scholarly excellence since its launch in 2021. It serves as a converging point for innovative studies and reviews that span the disciplines of chemistry and molecular medicine, reflected in its Q2 and Q3 quartile rankings in relevant categories for 2023. Situated in France, the journal is accessible globally, ensuring that researchers, professionals, and students can easily engage with significant findings and methodologies in medicinal chemistry. The open access model facilitates the dissemination of knowledge, bridging gaps between laboratory research and practical applications in drug development. By fostering collaboration and highlighting emerging trends, the European Journal of Medicinal Chemistry Reports plays a crucial role in shaping the future of therapeutic innovations.

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

CURRENT PROTEIN & PEPTIDE SCIENCE, published by Bentham Science Publishers, is a pivotal journal dedicated to the dynamic and rapidly evolving fields of protein and peptide research. With an ISSN of 1389-2037 and an E-ISSN of 1875-5550, this esteemed journal serves as a platform for disseminating cutting-edge findings from various disciplines, including biochemistry, cell biology, and molecular biology. Recognized for its influence with a 2023 Scopus ranking placing it within the top quartiles of its categories—Q3 in Biochemistry, Q4 in Cell Biology, and Q2 in Medicine—the journal not only enhances the visibility of critical research but also supports the academic community in advancing our understanding of the molecular foundations of life. Established in 2000 and running through 2024, CURRENT PROTEIN & PEPTIDE SCIENCE is positioned to cater to the interests of researchers, professionals, and students alike, providing them with open access to vital knowledge that fuels innovation and scientific inquiry in the United Arab Emirates and beyond.

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

Natural Product Communications is an esteemed open-access journal published by SAGE Publications Inc, dedicated to the exploration and dissemination of knowledge concerning natural products in diverse fields, including Complementary and Alternative Medicine, Drug Discovery, and Pharmacology. Since its inception in 2006 and continuing through its converged years until 2024, the journal has gained recognition with a robust focus on plant science and the medicinal properties of natural products. With a commendable impact factor reflected in its category quartiles (Q3 across key domains), Natural Product Communications serves as a vital resource for researchers and professionals who aim to further the understanding of the therapeutic potential of natural compounds. As an open-access journal since 2020, it ensures wide accessibility to its published research, thereby facilitating collaboration and innovation within the scientific community. This commitment to excellence makes Natural Product Communications a crucial platform for advancing research in the holistic and pharmacological sciences.

ACS Bio & Med Chem Au, published by the esteemed American Chemical Society, stands at the forefront of interdisciplinary research within the realms of biochemistry, drug discovery, pharmaceutical sciences, and molecular biology. With an impressive Impact Factor indicative of its rigorous academic standards and significant contributions to the field, this open-access journal is committed to disseminating high-quality research that drives innovation and advancements in biosciences and medicinal chemistry. Since its inception in 2021, the journal has rapidly earned recognition, achieving a commendable Q1 ranking in multiple categories, including Biochemistry, Drug Discovery, and Pharmaceutical Science, while also making strides in Molecular Biology. Researchers, professionals, and students alike can explore pioneering studies that bridge gaps between laboratory research and clinical applications, fostering collaborative efforts towards novel therapeutic strategies. With a focus on enhancing accessibility and engagement within the scientific community, ACS Bio & Med Chem Au is poised to impact the future of biomedical research significantly.

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

Protein Journal, published by Springer, stands as a significant academic resource in the fields of Analytical Chemistry, Biochemistry, Bioengineering, and Organic Chemistry. Since its inception in 1996, the journal has dedicated itself to the dissemination of high-quality research focused on protein chemistry and its biomedical applications. With an impressive impact reflected in its classification as a Q2 journal in Analytical Chemistry and Q3 in both Biochemistry and Bioengineering as of 2023, it provides an essential platform for researchers and practitioners to share their findings. The journal embraces the open-access model, enhancing accessibility to cutting-edge research. The Protein Journal is crucial for academicians, industry professionals, and students, catering to their need for rigorous scientific discourse and innovative discoveries in protein studies. With an established track record of converging over two decades of knowledge and research, it continues to influence and shape the advancements in this vital area of science.